14.2 Abnormal Uterine Bleeding, Fibroids, Endometriosis, and Pelvic Inflammatory Disease
Key Takeaways
FIGO PALM-COEIN classifies abnormal uterine bleeding of uterine origin outside pregnancy into structural and non-structural causes. Check for cervical, vaginal and pregnancy-related bleeding separately.
Assess haemodynamic stability and check for pregnancy when possible. Persistent intermenstrual bleeding with risk factors for endometrial pathology warrants specialist investigation. In the NICE heavy-bleeding pathway, assess the cavity with outpatient hysteroscopy and consider biopsy at the same procedure.
Consider a levonorgestrel intrauterine system first for suitable heavy menstrual bleeding with no identified pathology, small fibroids without cavity distortion, or adenomyosis. Tranexamic acid and a suitable NSAID are non-hormonal options. Device duration depends on the indication.
Disabling dysmenorrhoea, deep dyspareunia, cyclical bowel or urinary symptoms and subfertility suggest endometriosis. Offer ultrasound and discuss early treatment. Use specialist imaging for suspected deep organ involvement and consider laparoscopy when empirical treatment is ineffective or inappropriate.
Treat clinically suspected PID promptly while awaiting tests. HSE AMRIC first-choice community triple therapy for eligible patients is ceftriaxone 1 g IM once, plus doxycycline 100 mg and metronidazole 400 mg orally every 12 hours for 14 days. Suspected PID in pregnancy, sepsis or a suspected tubo-ovarian abscess needs emergency assessment.
Abnormal Uterine Bleeding and FIGO PALM-COEIN
Abnormal uterine bleeding (AUB) in the reproductive years includes changes in the frequency, regularity, duration or amount of bleeding, and bleeding between periods. Heavy menstrual bleeding (HMB) is bleeding that interferes with physical, social, emotional or material quality of life. Ask about flooding, night-time changes and days missed from work or school to understand the impact. PALM-COEIN describes causes of bleeding from the uterine corpus outside pregnancy. Examine for a cervical or vaginal source when the history suggests one. More than one cause can coexist, such as a fibroid and ovulatory dysfunction.
Structural causes (PALM)
- P — Polyp: Endometrial polyps can cause irregular or intermenstrual bleeding. A suspected cavity lesion guides the choice of hysteroscopy or imaging. A polyp on the cervix is a separate potential bleeding source on speculum examination.
- A — Adenomyosis: Endometrial glands and stroma within the myometrium can cause heavy, painful periods. A bulky, tender uterus raises suspicion.
- L — Leiomyoma: Benign smooth muscle tumours. The relationship to the cavity helps explain bleeding and guides the feasibility of hysteroscopic treatment.
- M — Malignancy and hyperplasia: Promptly evaluate suspicious bleeding patterns and relevant endometrial cancer risks. Early hyperplasia or malignancy can be present with a normal-sized uterus.
Non-structural causes (COEIN)
- C — Coagulopathy: Consider von Willebrand disease and other bleeding disorders, especially with heavy periods since menarche and recurrent epistaxis, bruising or bleeding after dental work.
- O — Ovulatory dysfunction: Irregular ovulation can produce prolonged oestrogen exposure without regular progesterone. Unpredictable cycles occur in adolescence, perimenopause and PCOS. Consider thyroid disease or hyperprolactinaemia when the clinical features support them.
- E — Endometrial: Consider a primary problem with local endometrial haemostasis after other relevant causes have been evaluated. This can present as heavy bleeding despite predictable cycles and no identified structural abnormality.
- I — Iatrogenic: Review hormonal medicines and contraception, anticoagulation, tamoxifen and devices such as a copper IUD. New or troublesome bleeding still needs assessment even when the patient uses a method that can change the bleeding pattern.
- N — Not otherwise classified: Examples include uterine arteriovenous malformation and a caesarean scar defect. Prior uterine procedures can help focus the differential.
Evaluate the bleeding pattern and choose the first investigation
- Assess stability. Ongoing heavy bleeding with syncope, hypotension or poor perfusion needs emergency assessment and resuscitation. If pregnancy is possible, check urine or serum hCG promptly. Contraception lowers the chance of pregnancy. A positive result with pain or bleeding changes the pathway to assessment for pregnancy complications, including ectopic pregnancy.
- Take a focused history and examine appropriately. Clarify when bleeding occurs, how long it lasts, whether it follows sex and whether it accompanies pain or pressure. Review medications, cycle history and fertility plans. Offer speculum or pelvic examination with consent when the symptoms suggest cervical, vaginal or pelvic pathology. Diagnostic assessment of symptoms proceeds even after a recent normal cervical screen.
- Investigate anaemia and other clues. Obtain a full blood count in HMB. Assess iron deficiency when indicated by the history and blood count. NICE NG88 does not recommend routine ferritin for every presentation with HMB. Check thyroid function if there are symptoms or signs of thyroid disease. Consider testing for a coagulation disorder if HMB began at menarche and there is a personal or family bleeding history.
- Select the test by the suspected pathology. The Irish menorrhagia pathway flags new or worsening bleeding over 45, persistent intermenstrual or postcoital bleeding, obesity, PCOS and tamoxifen use for gynaecological assessment. For HMB with suspected intracavitary pathology or endometrial risk factors, NICE NG88 recommends outpatient hysteroscopy with endometrial biopsy during the procedure when risk is elevated. Examples include persistent intermenstrual bleeding, infrequent heavy bleeding with obesity or PCOS, tamoxifen use and failed treatment. Transvaginal ultrasound is useful for suspected adenomyosis. Pelvic ultrasound can assess an enlarged uterus or pelvic mass. In a menstruating patient the endometrium varies with cycle timing. Assess the pattern, focal irregularity and clinical context together. Hysteroscopy can locate a lesion and allow targeted sampling.
Worked distinction: Gradually increasing cyclic blood loss with pelvic pressure and a palpable enlarged uterus directs attention to pelvic ultrasound and fibroid location. Progressive heavy bleeding with persistent intermenstrual spotting, obesity and an irregular cavity finding calls for specialist cavity assessment and tissue diagnosis even if the uterus feels normal.
Treatment of heavy menstrual bleeding
Discuss bleeding burden, likely cause, pain, anaemia, contraception and plans for pregnancy. Treat associated iron deficiency. Investigate alarm features and offer individualised symptom relief while awaiting evaluation.
| Treatment | How it helps | Selection and practical decisions |
|---|---|---|
| Levonorgestrel intrauterine system (LNG-IUS) | Local progestogen suppresses the endometrium and reduces bleeding | NICE NG88 considers this first for suitable patients with no identified pathology, fibroids under 3 cm that do not distort the cavity, or suspected or diagnosed adenomyosis. Explain initial spotting and allow time to assess benefit. |
| Tranexamic acid | Reduces fibrinolysis and menstrual blood loss | Non-hormonal option started with heavy flow. Check the oral product, thrombotic history and renal function. Active thromboembolic disease is a contraindication to Cyklokapron tablets. |
| NSAID such as mefenamic acid | Inhibits prostaglandin synthesis, reducing pain and blood loss | Consider when dysmenorrhoea accompanies heavy periods. Check gastrointestinal bleeding history, kidney function and previous aspirin or NSAID hypersensitivity, including bronchospasm. |
| Combined hormonal contraception | Suppresses ovulation and reduces endometrial proliferation | Can reduce dysmenorrhoea and provide more predictable bleeding as well as contraception. Check eligibility, including migraine with aura, thrombotic history, smoking and cardiovascular risk. |
| Cyclical oral progestogens | Reduce heavy bleeding by acting on the endometrium | Can be considered if an LNG-IUS is unsuitable or declined. Verify the preparation and regimen. A therapeutic progestogen regimen for bleeding may provide no reliable contraception. |
| Endometrial ablation | Treats the endometrium to reduce bleeding | Consider in selected patients who wish to avoid hysterectomy and have no further pregnancy plans. Use effective contraception afterward because pregnancy remains possible and is hazardous. Investigate the cavity and exclude significant disease before treatment. |
| Hysterectomy | Removes the source of uterine bleeding | Discuss major surgery, loss of fertility, risks and alternatives. It can offer definitive control when conservative measures are unsuitable or unacceptable or have failed. |
One device, different indications: The Irish Mirena 52 mg authorisation provides up to eight years of contraception. For idiopathic HMB it provides five years of treatment. If symptoms return, remove or replace it. If symptoms remain controlled after five years, continued use may be considered up to eight years. For endometrial protection during oestrogen therapy, replace or remove it at five years. Check the actual device and indication when advising on replacement.
Uterine leiomyomas (fibroids)
Fibroids are benign smooth muscle tumours of the myometrium whose growth is hormone sensitive. Some are incidental. Cavity involvement is particularly relevant for heavy bleeding. A fibroid projecting outside the uterus can cause pressure, urinary frequency or bowel symptoms without prominent bleeding. An imaging report should describe the relationship to both endometrium and serosa before the clinician decides what can be reached hysteroscopically.
FIGO anatomical subtypes
| Type | Relationship |
|---|---|
| 0 | Pedunculated and entirely intracavitary |
| 1 or 2 | Submucosal with less than 50% intramural (1), or at least 50% intramural (2) |
| 3 | Entirely intramural and in contact with the endometrium, without distorting the cavity |
| 4 | Entirely intramural without contact with the endometrium or serosa |
| 5 or 6 | Subserosal with at least 50% intramural (5), or less than 50% intramural (6) |
| 7 | Pedunculated subserosal |
| 8 | Other location, for example cervical or parasitic |
| Hybrid | Two numbers indicate the relationships to the endometrium and serosa respectively, for example 2–5 |
Match management to anatomy and pregnancy plans
- Bleeding control: An LNG-IUS can be suitable when the fibroid does not distort the cavity. Tranexamic acid and NSAIDs can control symptoms while specialist treatment is arranged. Discuss treatment options in specialist care for larger, multiple or substantially symptomatic fibroids.
- Specialist medical treatment: Short-term GnRH agonist treatment may be considered before surgery for an enlarged or distorted uterus. It suppresses ovarian hormone production after initial stimulation. Use and duration depend on the preparation, indication and tolerability, including bone effects. An oral GnRH antagonist suppresses gonadotrophins without an initial flare. The EU-authorised relugolix–estradiol–norethisterone combination is one specialist option for moderate to severe fibroid symptoms in adults of reproductive age.
- Uterine artery embolisation (UAE): Interventional radiology reduces blood supply to fibroids and can improve bleeding and pressure symptoms while preserving the uterus. The Irish model of care provides the option for suitable patients. FIGO fertility guidance advises against UAE when planning pregnancy. Discuss reproductive goals before choosing UAE or a surgical approach.
- Surgery: Consider hysteroscopic removal for accessible symptomatic submucosal fibroids. Greater intramural extension can make removal more complex. Myomectomy preserves the uterus and is an option when a symptomatic or fertility-relevant fibroid warrants removal. Hysterectomy is a definitive option for uterine symptoms when pregnancy is no longer desired.
Worked distinction: A patient with heavy bleeding and an accessible type 0 fibroid who hopes to conceive may benefit from hysteroscopic removal. A patient with multiple subserosal fibroids and significant pressure needs a discussion about the cause of those symptoms and which options address bulk. Removing the endometrium would leave the subserosal lesions in place.
Endometriosis and adenomyosis
Recognise the patterns
Endometriosis is a chronic inflammatory condition with endometrial-like tissue outside the uterus. Ovarian involvement can produce endometriomas containing old blood. Peritoneal, uterosacral and rectovaginal disease can cause pain, and disease affecting bowel, bladder or ureter may need a multidisciplinary approach. Consider it with disabling dysmenorrhoea, deep dyspareunia, chronic pelvic pain, cyclical dyschezia, urinary symptoms or infertility. Several features may coexist, and a patient may have just one. Examine for a mass, reduced pelvic organ mobility or posterior tenderness or nodularity when appropriate. A normal examination is possible.
Investigation and treatment in the Irish pathway
- Initial imaging: Offer transvaginal ultrasound, or consider transabdominal ultrasound when a vaginal approach is unsuitable. Homogeneous low-level echoes in an ovarian cyst can suggest an endometrioma. Use specialist imaging such as MRI as appropriate when deep bowel, bladder or ureteric involvement is suspected. Superficial peritoneal disease can be missed on imaging. Serum CA-125 is unsuitable as a diagnostic test.
- Early support and referral: Discuss empirical treatment for suspected disease and refer to gynaecology for severe, persistent or recurrent symptoms, examination findings, associated infertility, ineffective or unsuitable initial therapy, or imaging suggesting an endometrioma or deep disease. Refer suspected or confirmed deep bowel, bladder or ureteric disease to a specialist endometriosis service.
- Laparoscopy: Consider when empirical treatment is ineffective or inappropriate, including with negative imaging. Inspect systematically and biopsy suspected lesions for histological confirmation. Lesions can vary in colour and appearance. An unrevealing biopsy alone cannot exclude the diagnosis. Surgery can be offered for pain and planned according to the sites involved, severity and preferences.
- Medication and fertility: Offer combined hormonal contraception or a progestogen as first-line hormonal treatment for pain when suitable. Specialist GnRH agonists or antagonists with add-back hormone treatment are second-line options. For someone trying to conceive, hormonal suppression does not improve spontaneous conception. Operative laparoscopy can improve the chance of ongoing pregnancy in stage I–II endometriosis with infertility. Endometrioma surgery requires individualised discussion of ovarian reserve, symptoms, previous surgery and fertility treatment plans. Hysterectomy is reserved for selected patients after conservative treatment has failed and future pregnancy is undesired. Symptoms may persist.
Adenomyosis
Adenomyosis involves endometrial glands and stroma within the myometrium. Heavy periods, dysmenorrhoea and a bulky, tender uterus are clues, and endometriosis and fibroids may coexist. Transvaginal ultrasound is generally the first investigation for suspected adenomyosis in a patient with HMB. Myometrial cysts and echogenic subendometrial lines or buds are direct ultrasound findings. A globular uterus, wall asymmetry and fan-shaped shadowing are indirect findings. Specialist imaging can clarify uncertainty. Management depends on symptoms and fertility goals. An LNG-IUS is an option for HMB, and hysterectomy is definitive treatment for the uterine disease when appropriate.
Pelvic inflammatory disease (PID)
PID usually results from ascending infection into the upper genital tract. It includes endometritis, salpingitis, tubo-ovarian abscess (TOA) and pelvic peritonitis. Gonorrhoea, chlamydia, Mycoplasma genitalium and mixed genital tract organisms are relevant. Clinical severity varies and mild symptoms can still precede tubal damage.
- History and examination: Pelvic or lower abdominal pain, altered discharge, deep dyspareunia or postcoital bleeding suggest PID. Ask about pregnancy risk, sexual exposures and symptoms suggesting another diagnosis. Pelvic tenderness and cervical motion tenderness support a clinical diagnosis. Consider appendicitis, ovarian torsion and ectopic pregnancy when the presentation warrants it. Sepsis, rebound or a pelvic mass can signal complicated disease.
- Pregnancy and sexual health tests: Obtain a pregnancy test. HSE AMRIC recommends testing for STIs, including HIV, hepatitis B, syphilis, gonorrhoea, chlamydia, trichomoniasis and M. genitalium, where possible before giving antibiotics. Assess hepatitis C testing by risk. Add gonorrhoea culture for susceptibility where possible. Treat on clinical suspicion while awaiting results. Negative lower-tract swabs do not exclude upper-tract infection.
- Imaging when indicated: Obtain urgent specialist assessment and imaging where an abscess or another urgent pelvic diagnosis is suspected. A complex adnexal mass with pelvic infection raises concern for TOA.
- Referral: Suspected cases generally warrant referral to genitourinary medicine. Severe symptoms, pregnancy, suspected abscess or a possible acute surgical diagnosis warrant emergency assessment. Pelvic pain with a positive pregnancy test requires evaluation of pregnancy location.
Irish community treatment and follow-up
For a suitable non-pregnant patient in the community, HSE AMRIC recommends ceftriaxone 1 g deep IM once, plus doxycycline 100 mg orally every 12 hours for 14 days and metronidazole 400 mg orally every 12 hours for 14 days. The combination covers gonorrhoea, chlamydia and anaerobes. Check allergy before ceftriaxone, and discuss alternatives with specialist services when appropriate. If a drug cannot be tolerated, assess severity and agree an appropriate plan rather than continuing a reduced empirical regimen. Refer positive M. genitalium results to a specialist sexual health service for management because resistance is common.
Review patients receiving community treatment within 72 hours. With little or no improvement, revisit the diagnosis and consider hospital referral. Earlier deterioration requires earlier assessment. Sepsis, inability to tolerate oral therapy and likely need for intervention, such as an abscess, are indications for hospital assessment and parenteral therapy. Inpatient antimicrobial and source-control plans depend on the presentation and local hospital policy.
Complications and prevention of recurrence
- Tubo-ovarian abscess: Suspect with pelvic pain, systemic illness or a complex adnexal mass. Involve gynaecology for parenteral antibiotics and assessment for image-guided drainage or surgery. Rupture with peritonitis or sepsis needs urgent source control.
- Fitz-Hugh–Curtis syndrome: Perihepatitis can cause pleuritic right upper quadrant pain or shoulder-tip pain with pelvic infection. Consider the pelvic and hepatobiliary differentials together.
- Long-term outcomes: Tubal injury can cause subfertility, ectopic pregnancy or chronic pelvic pain. Arrange follow-up, support partner testing and treatment according to sexual health guidance and advise avoiding sex until treatment is complete for the patient and any partners who need it. The laboratory usually initiates notification if chlamydia, gonorrhoea or trichomoniasis is diagnosed.
Worked distinction: A patient with localised pelvic tenderness and no systemic illness may be suitable for immediate community treatment with planned review. Fever, vomiting and a tender pelvic mass raise concern for an abscess and inability to tolerate oral treatment. Repeat prescriptions cannot substitute for emergency specialist assessment.
A 48-year-old woman presents to the gynaecology clinic with nine months of increasingly heavy, prolonged periods and persistent intermenstrual spotting. Her BMI is 32 kg/m². The pregnancy test is negative and there is no visible cervical lesion. Her uterus is normal in size on examination. Transvaginal ultrasound shows an irregular endometrial contour. What is the most appropriate next step?
Reassure the patient that heavy bleeding is normal during the perimenopause and schedule review in 12 months
Use tranexamic acid alone as definitive treatment
Insert a levonorgestrel-releasing intrauterine system (LNG-IUS) without further diagnostic workup
Arrange hysteroscopy with endometrial sampling
A 29-year-old woman reports disabling dysmenorrhoea, deep dyspareunia and no conception after 14 months of trying. Bimanual examination finds posterior nodularity. Transvaginal ultrasound shows a 4 cm left ovarian lesion with homogeneous low-level echoes and no internal vascularity. She hopes to conceive soon. What is the most appropriate next step?
Refer for gynaecology assessment of suspected endometriosis and associated infertility
Measure serum CA-125 as the sole diagnostic test
Start long-term ovulation suppression to improve her chance of spontaneous conception
Arrange hysteroscopy and endometrial curettage to confirm extrauterine lesions
A 21-year-old sexually active woman presents to her GP with a 4-day history of bilateral lower abdominal aching and purulent yellow vaginal discharge. She has also noted pain during deep intercourse and spotting after intercourse. Her temperature is 37.8°C, pulse 86 bpm, and BP 118/74 mmHg. Abdominal examination demonstrates mild bilateral lower quadrant tenderness without rebound or guarding. Bimanual examination reveals exquisite cervical motion tenderness ('chandelier sign') and bilateral adnexal tenderness. Urine pregnancy test is negative. Endocervical swabs for nucleic acid amplification testing (NAAT) are taken. She has no known antibiotic allergies, can take oral medication and is suitable for community treatment. What is the HSE AMRIC first-choice empirical regimen?
Oral ciprofloxacin 500 mg single dose plus oral azithromycin 1 g single dose
Intramuscular ceftriaxone 1 g single dose plus oral doxycycline 100 mg twice daily for 14 days plus oral metronidazole 400 mg twice daily for 14 days
Oral amoxicillin-clavulanic acid 625 mg three times daily for 7 days
Oral metronidazole 400 mg twice daily for 7 days monotherapy
Sections you finish are checked off in the contents.